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ABSTRACT
While the fertilized egg inherits its nuclear DNA from both parents, the mitochondrial DNA is
strictly maternally inherited. Cells contain multiple copies of mtDNA, each of which encodes 37
genes, which are essential for energy production by oxidative phosphorylation. Mutations can
be present in all, or only in some copies of mtDNA. If present above a certain threshold, patho-
genic mtDNA mutations can cause a range of debilitating and fatal diseases. Here, we provide
an update of currently available options and new techniques under development to reduce the
risk of transmitting mtDNA disease from mother to child. Preimplantation genetic diagnosis
(PGD), a commonly used technique to detect mutations in nuclear DNA, is currently being
offered to determine the mutation load of embryos produced by women who carry mtDNA
mutations. The available evidence indicates that cells removed from an eight-cell embryo are
predictive of the mutation load in the entire embryo, indicating that PGD provides an effective
risk reduction strategy for women who produce embryos with low mutation loads. For those
who do not, research is now focused on meiotic nuclear transplantation techniques to uncouple
the inheritance of nuclear and mtDNA. These approaches include transplantation of any one of
the products or female meiosis (meiosis II spindle, or either of the polar bodies) between
oocytes, or the transplantation of pronuclei between fertilized eggs. In all cases, the transferred
genetic material arises from a normal meiosis and should therefore, not be confused with clon-
ing. The scientific progress and associated regulatory issues are discussed. STEM CELLS
2015;33:639–645
INTRODUCTION
The fertilized human egg contains two types
of DNA: the nuclear DNA, which is packaged
into chromosomes, is inherited from both
parents and enclosed in two haploid pronuclei
(PN). By contrast, the DNA within mitochon-
dria (mtDNA) consists of small (16.5 kb) circu-
lar molecules, which are packaged into
nucleoprotein complexes, called nucleoids, and
inherited exclusively through the female line-
age [1]. The small number of mitochondria
introduced by the sperm is targeted for
destruction by a conserved autophagic mecha-
nism known as mitophagy [2]. Thus, the
mtDNA (>100,000 copies) present in the
human oocyte [3] constitutes the founder pop-
ulation for the mitochondria in all the cell
types of the resulting embryo.
According to the endosymbiotic theory,
mtDNA is the remnant of the genome of a
once free-living a-proteobacterium, which has
been engulfed by the ancestor of the modern-
day eukaryotic cell [4, 5]. As a result, the outer
membrane of mitochondria is related to the
eukaryotic plasma membrane while the inner
membrane has retained some prokaryotic
properties. While the main function of mito-
chondria is to produce ATP by oxidative phos-
phorylation (OXPHOS), they have acquired
additional functions during evolution including
induction of apoptosis [6, 7], calcium homeo-
stasis [8], and the formation of iron sulfur
clusters [9]. Although mitochondria contain
their own DNA, their biological functions are
dependent upon nuclear-encoded genes,
whose protein products are imported across
the mitochondrial membranes [10]. Of the
estimated 1,100 genes required for mito-
chondrial function in humans, only 37 are
encoded by the mtDNA. These include 13 poly-
peptides, together with two rRNAs and 22
tRNAs required for mitochondrial protein syn-
thesis [11]. All proteins encoded by mtDNA
are components of the OXPHOS system, which
consists of five large protein complexes
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TRANSLATIONAL AND CLINICAL
RESEARCH
containing a total of 80–100 subunits [11]. Thus, the produc-
tion of ATP requires direct interaction between proteins
encoded by the mitochondrial and the nuclear genome.
INHERITANCE OF MITOCHONDRIAL DNA DISEASE
Since mitochondrial genes are essential for the OXPHOS system,
mutations in mtDNA can reduce mitochondrial ATP production,
which particularly affects organs with high energy require-
ments, such as the brain, muscle, and heart [12, 13]. Mutations
can be present in all copies of mtDNA (homoplasmy), or in only
a fraction of copies (heteroplasmy), and the severity of clinical
symptoms is determined by the ratio of mutated to wild-type
mtDNA [14]. Diseases associated with mtDNA mutations include
a broad range of debilitating and fatal conditions, none of which
can be currently cured [12, 13]. Whereas the estimated inci-
dence of mtDNA disease in adults is 1 in 5,000 [15], low levels
of pathogenic mutations are more prevalent and have been
detected in 1 out of every 200 births [16, 17].
Mutated copies of mtDNA present in the oocyte are trans-
mitted to the embryo. In the case of women with homoplasmic
mtDNA mutations, the entire complement of mtDNA carries the
mutation therefore all oocytes are affected. By contrast, the
oocytes of women with heteroplasmic mtDNA contain variable
mtDNA mutation loads. This is thought to be due to a phenom-
enon known as the mtDNA genetic bottleneck, which involves a
dramatic decline in mtDNA copy number during female germ
cell development, giving rise to a statistical sampling effect
which results in marked variation in the level of heteroplasmy
between individual oocytes [11, 18, 19]. As a consequence, the
transmission of mtDNA disease from a woman with a hetero-
plasmic mtDNA mutation to her children is unpredictable. Given
the difficult reproductive choices faced by women carrying
pathogenic mtDNA mutations, there is a growing interest in the
development of assisted reproductive technologies to prevent
transmission of mtDNA mutations from mother to child.
PREIMPLANTATION GENETIC DIAGNOSIS FOR DETECTING MTDNA
MUTATIONS
Preimplantation genetic diagnosis (PGD) is an established pro-
cedure for preventing transmission of mutations in nuclear
DNA. Embryos are tested by removing one or more cells for
genetic analysis. Unaffected embryos are then chosen for
transfer to the uterus. In recent years, PGD has been applied
to reduce the risk of transmitting mtDNA disease. However,
clinical decisions related to the transfer of embryos following
PGD for mtDNA mutations are complicated by the need to
define thresholds of heteroplasmy, which can vary between
mutations [14]. The question of whether the sampled cells
are representative of the entire embryo is also fundamental
to the success of PGD for reducing the risk of mtDNA disease.
A number of strategies could be used to predict the
mtDNA mutation load in embryos. For example, it has been
proposed that polar bodies, which are the by-products of
female meiosis, provide a reliable and minimally invasive
proxy for the oocyte mutation load [20, 21]. However, other
studies in mouse [22] as well as humans [23, 24] indicate a
low correlation in mtDNA mutation load between the polar
bodies and the oocyte. This may be linked to the highly asym-
metric segregation of mitochondria during female meiosis
[25]. An alternative and commonly used approach is to
remove cells from the developing embryo, which is typically
performed at the eight-cell stage. Data from human embryos
indicate a low variability in the level of heteroplasmy between
the blastomeres of cleavage-stage embryos [26–30]. It has
also been reported that trophectoderm cells biopsied from
human blastocysts are representative of the mtDNA mutation
load in the inner cell mass (ICM) [26]. However, there are
conflicting reports on the mutation load of a child born fol-
lowing trophectoderm biopsy [26, 31], which may be linked
to the assays used to measure mtDNA.
Experimental systems to study the segregation of variant
mtDNA during early development include either embryos pro-
duced by females with heteroplasmic mtDNA mutations or
those in which heteroplasmy has been induced artificially. How-
ever, an elegant set of experiments performed by Meirelles and
Smith indicated that variant mtDNA segregates more uniformly
between blastomeres when it is inherited through the germ
line rather than introduced via karyoplast or cytoplast fusion
with a fertilized egg [32]. Interestingly, the widest variation was
observed following cytoplast fusion [32]. Consistent with this, it
has recently been reported that fusion of bisected oocytes
from rhesus macaque females with distinct mtDNA haplotypes
resulted in embryos with widely varying levels of heteroplasmy
between cells [33]. It seems likely that in this experimental sys-
tem, the orientation of the plane of the first embryonic cleav-
age relative to the plane of oocyte fusion is crucial for
determining the fate of variant mtDNA. Indeed, it has been
suggested previously that experimental models involving artifi-
cially induced heteroplasmy may be of limited relevance to our
understanding of how inherited mtDNA mutations segregate
during early human development [29].
In conclusion, current evidence suggests that there are no
major shifts in the segregation of inherited mtDNA mutations
during early embryonic development. Thus, blastomeres
removed from eight-cell embryos are likely to provide a reli-
able indication of the mutation load in the entire embryo.
Therefore, PGD constitutes a promising risk reduction strategy
for affected families.
UNCOUPLING THE INHERITANCE OF NUCLEAR AND MTDNA TO
PREVENT TRANSMISSION OF MTDNA DISEASE
While PGD can be used to identify embryos with low muta-
tion loads, it is not effective for women with homoplasmic
mtDNA mutations or women with heteroplasmic mtDNA
mutation loads close to the disease threshold. To address this
issue, recent research has focused on the development of
techniques to reduce the risk of transmission of mtDNA dis-
ease by transplanting the nuclear genome between oocytes
before or after fertilization with the aim of uncoupling the
inheritance of nuclear and mtDNA. In principle, this would
enable women who carry mtDNA mutations to have a geneti-
cally related child while greatly reducing the risk of transmit-
ting mtDNA mutations.
Transplantation of the nuclear genome can be either per-
formed on the fertilized egg, or before the oocyte is fertilized,
for which the process of female meiosis offers several options
(Fig. 1). Throughout its growth phase, the oocyte remains
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arrested in prophase of meiosis I with a very large nucleus
known as the germinal vesicle (GV). The GV contains bivalent
chromosomes formed during meiotic recombination when
replicated maternal and paternal homologs become physically
linked at sites of reciprocal exchange of DNA between non-
sister chromatids to form crossovers, which in cytological stud-
ies are known as chiasmata [34]. In the sexually mature
female, a hormonal stimulus induces the fully grown oocytes
to enter M phase of meiosis I. During the first meiotic division,
crossovers are resolved and half of the resulting dyad chromo-
somes (each containing two chromatids) are expelled into the
first polar body. This occurs shortly before the oocyte is ovu-
lated. The dyad chromosomes remaining in the oocyte align on
the meiosis II spindle and the oocyte remains arrested at this
stage until sperm entry. This triggers the second meiotic divi-
sion (MII) during which one chromatid of each chromosome is
retained in the oocyte while the other is expelled into the sec-
ond polar body. The haploid genomes from the oocyte and the
sperm are then separately packaged into pronuclei (Fig. 1).
Thus, in contrast to spermatogenesis, which produces four
equal-sized gametes, female meiosis produces only one
gamete capable of fertilization, the oocyte, which retains a
haploid set of chromosomes and most of the cytoplasm.
The technique of pronuclear transfer (PNT) between fertil-
ized mouse eggs (zygotes) was pioneered by McGrath and
Solter more than 3 decades ago [35]. The procedure involves
treatment of zygotes with microtubule and actin-
depolymerizing drugs to facilitate removal of the pronuclei
without the need to penetrate the plasma membrane. The PN
are pinched-off within a small volume of membrane-enclosed
cytoplasm, known as a karyoplast, which is subsequently
fused with an enucleated zygote. Membrane fusion is facili-
tated by inactivated Sendai virus or an electrical pulse [35,
36]. However, the latter is not well tolerated by human
oocytes and zygotes [37, 38]. The experiments of McGrath
and Solter [35] revealed that PNT between zygotes from dif-
ferent mouse strains can produce healthy and normally repro-
ducing offspring. The possibility of using PNT to prevent
transmission of mtDNA disease (Fig. 2A) was first proposed in
the 1990s [21]. Later experiments using zygotes from a mouse
carrying a rearrangement in the mtDNA indicated that the
fraction of mutant mtDNA could be greatly reduced by PN
transfer into enucleated zygotes from females with wild-type
mtDNA [21]. More recently, proof of concept experiments
with abnormally fertilized eggs explored the potential of PNT
in human zygotes [38]. Despite their large size (25–30 mm),
transplantation of PN between human zygotes was technically
feasible and compatible with development to the blastocyst
stage [38]. After optimization of the procedure, the level of
the mtDNA “carried-over” within the karyoplast was reduced
to <2% on average [38], which is well below the disease
threshold for mutations studied to date [14].
In relation to transplantation of the nuclear genome before
the oocyte is fertilized, it is, in theory, possible to harvest imma-
ture oocytes and to transplant the GV (Fig. 1). However, this
would require in vitro maturation of oocytes from the GV stage
to the MII stage, which is the stage at which oocytes are con-
ventionally harvested for IVF treatment. However, GV transfer
would necessitate removal of the cumulus cells, which are
thought to be important for normal maturation of the oocyte
[39, 40]. It is therefore likely that successful adoption of this
approach would require strategies that compensate for the
absence of an intact cumulus-oocyte complex. So far, there are
no reports of successful GV transfer between human oocytes.
Currently, the most promising strategy for human oocytes is
to transfer the nuclear genome between MII-arrested oocytes
(Fig. 2B). In contrast to the GV or the PN stage, the MII oocyte
chromosomes are not enclosed within a nuclear membrane.
Instead, they are aligned on the MII spindle, poised to undergo
anaphase II following sperm entry. As conventional light
Figure 1. Schematic drawing showing progression from prophase of meiosis I (GV stage) to completion of meiosis II following fertiliza-
tion. The diploid maternal genome contained in the large nucleus (GV) of the prophase I oocyte is packaged into bivalent chromosomes
formed during meiotic recombination when pairs of replicated parental homologs become linked at the sites of reciprocal DNA
exchange. Oocytes enter M phase of first meiotic division (MI) in response to hormonal stimulation and undergo anaphase of MI when
bivalents are converted to dyad chromosomes, consisting of a pair of chromatids (at least one of which is a recombinant). Half of the
dyads are ejected in the first polar body. The dyads remaining in the oocyte align on the second meiotic division (MII) spindle poised to
undergo anaphase in response to sperm entry. During anaphase of MII dyads are resolved to single chromatids and half is lost in the
second polar body. The chromatids remaining in the oocyte become surrounded by a nuclear membrane to form the female pronucleus.
The products of the first and second meiotic divisions each contain a unique genome. Abbreviation: GV, germinal vesicle.
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microscopy cannot visualize the spindle or chromosomes, the
standard practice is to use liquid crystal birefringence, which
enables spindle visualization [37, 41–43]. However, this
approach may be problematic in cases where chromosomes
become misaligned or scattered, as has been reported for
oocytes from older women [44]. The use of a fluorescent DNA
dye such as Hoechst is not desirable, because they intercalate
into DNA and require damaging UV light for excitation.
Despite these technical challenges, proof-of-concept
experiments with rhesus macaque oocytes resulted in the birth
of healthy monkeys with undetectable mtDNA carryover [45].
Follow-up experiments using human oocytes indicated that MII
spindle transfer (MST) results in a low level of mtDNA carry-
over [41, 43]. However, fertilization of MST oocytes resulted in
a high incidence (48%) of zygotes containing an abnormal
number of pronuclei [41]. This was, at least in part, due to pre-
mature chromatid separation in the absence of second polar
body formation, causing both sets of maternal chromatids to
remain in the oocyte. Interestingly, abnormal numbers of pro-
nuclei were not observed upon fertilization of MST oocytes
from monkey [45], indicating that human oocytes are more
sensitive to premature chromatid separation. Nevertheless, a
high proportion of those that underwent normal fertilization
developed to the blastocyst stage [41]. However, no data were
presented on blastocyst morphology, which correlates closely
with implantation potential [46, 47].
Embryonic stem cells (ESCs) derived from human blasto-
cysts produced following MST showed normal expression of
pluripotency markers [41, 43], normal metabolic profiles [43],
and those that were derived from fertilized embryos showed
a normal karyotype [41]. Analysis of mtDNA revealed that
very low levels, typically <1%, of karyoplast-associated
mtDNA persisted in ESC lines and their derivatives [41, 43].
Together, these data indicate that the epiblast precursor cells
from human MST blastocysts behave normally following
explantation of the ICM. However, the establishment of viable
Figure 2. Schematic drawing showing approaches to meiotic genome transfer that has been tested in human oocytes/zygotes for
potential clinical application to reduce the risk of transmitting mtDNA disease. (A): Pronuclear transfer: MII-arrested oocytes obtained
from the affected woman and a healthy donor are fertilized and the pronuclei are transferred in a karyoplast from the affected woman’s
fertilized egg to the enucleated donor egg. (B): Spindle transfer: oocytes obtained from an affected woman and a healthy donor are
enucleated by removal of the MII spindle and its chromosomes in a karyoplast. The karyoplast from the affected woman is fused with
the enucleated oocyte from the healthy donor. Reconstituted oocytes are then fertilized and undergo the second meiotic division fol-
lowed by formation of the male and female pronuclei. Abbreviations: MII, second meiotic division; PN, pronuclei.
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pregnancies also requires that the blastocyst’s trophectoderm
and primitive endoderm lineages are competent to develop
into the placenta and yolk sac, respectively. Therefore, it will
be important to investigate in more detail blastocyst morphol-
ogy, lineage specification, and gene expression of blastocysts
following MST and PNT.
More recently, experiments in mice indicated that the
oocyte polar bodies could be used as a source of nuclear
DNA with minimal carryover of mtDNA [48]. Fusion of first
polar bodies with enucleated, unfertilized oocytes resulted in
efficient blastocyst formation following fertilization and six
pups were born [48]. Second polar bodies, which, like the
pronucleus, contain one chromatid from each chromosome,
were fused with zygotes from which the female pronucleus
had previously been removed. Blastocysts and live births
were obtained, but less efficiently compared with the first
polar body/oocyte fusions [48]. If found to be effective in
humans, the use of polar bodies as a source of additional
haploid maternal genomes has the potential to reduce the
number of oocytes required from women affected by mtDNA
mutations.
In conclusion, transplantation of the nuclear genome can
be performed at various stages of female meiosis and the hap-
loid genomes generated following fertilization contain a unique
mix of genes, reshuffled during meiotic recombination and sto-
chastically inherited during the subsequent meiotic divisions.
Thus, to avoid any possible confusion with the process of clon-
ing, it is important to stress that all products of meiosis (pronu-
clei and polar bodies) are genetically unique. Given the range
of possible approaches to transplanting the nuclear genomes
of the oocyte or zygote, an umbrella term such as meiotic
nuclear transfer Mei-NT might best describe the general
approach, while making it clearly distinct from cloning.
TOWARD CLINICAL TREATMENT
In many countries, the introduction of these novel Mei-NT
techniques as clinical treatments to prevent transmission of
mtDNA disease will involve changes to existing regulations
governing assisted conception treatments. In the U.K., amend-
ments to the Human Fertilization and Embryology Act in 2008
included provision for the law to be changed by Parliament to
enable the Human Fertilization and Embryology Authority
(HFEA) to licence the use of new techniques for the purpose
of preventing transmission of mtDNA disease. The ethical
issues associated with the introduction of these techniques
have been comprehensively reviewed elsewhere [49]. Follow-
ing a number of broadly supportive public consultations, the
proposed changes to current legislation have been drafted.
The next step will be a debate followed by a vote in both
Houses of Parliament. In the event that Parliament approves
the changes, IVF centers would be required to apply to the
HFEA for a licence to offer the techniques in clinical treat-
ment. This would be subject to additional corroborative evi-
dence on the robustness and efficiency of PNT/MST as
specified by a panel of experts convened by the HFEA in the
U.K. [50].
In the U.S., the Food and Drug Administration recently
held a public horizon-scanning meeting to explore whether it
would be appropriate to approve clinical trials to test the
safety and efficacy of MST/PNT. In contrast to the U.K., the
use of these techniques might not necessarily be confined to
reducing the risk of mtDNA disease. It has been proposed
that transfer of the MII spindle from the oocyte of an older
woman to the enucleated oocyte of a younger woman might
be effective in ameliorating the effects of female age on fertil-
ity [51]. However, it is been well established that the majority
of MII human oocytes from older women are either already
aneuploid [52], or contain pairs of single chromatids [53, 54],
which have a high risk of missegregating during MII. Currently,
there is no known mechanism whereby these chromosomal
aberrations could be reversed by transferring the MII spindle
to the enucleated oocyte obtained from a younger woman.
Given the low levels of mtDNA carryover during PNT [38]
and MST [41, 43] in humans, and polar body transfer in mice
[48], these techniques are likely to be highly effective in
reducing the risk of mtDNA disease in children of affected
women. However, it has been proposed that coevolution of
the mitochondrial and maternal nuclear genomes might result
in adverse effects arising from the creation of a new combina-
tion of mtDNA and nuclear DNA. Such concerns are based on
evidence of adverse outcomes following experimentally
induced heteroplasmy in mice and Drosophila [55]. However,
there is no evidence for incompatibilities between nuclear
and mitochondrial genotypes in humans, even in couples with
divergent mitochondrial haplotypes [56]. Thus, the theoretical
risk associated with incompatibilities of nuclear and mitochon-
drial genomes seems remote in comparison to the very real
risk of serious disease in children of women who carry high
levels of pathogenic mtDNA mutations.
Ongoing in vitro experiments to optimize the techniques
and to test the effects of Mei-NT on preimplantation develop-
ment will require a supply of donated human oocytes. Fur-
thermore, a continued supply will be required in the event of
the techniques being translated to clinical treatment. Practices
related to oocyte donation vary widely [57]. Commonly used
options include so called “egg sharing,” in which women
undergoing IVF treatment donate half of their oocytes for use
by others. Such schemes are already well established as a
source of donated oocytes for IVF treatment [58, 59]. Alterna-
tively, oocytes can be obtained from women who donate
altruistically [60, 61].
In conclusion, while PGD can reduce the risk of transmitting
mtDNA disease, it relies on the production of embryos with
low levels of mtDNA mutation. By contrast, Mei-NT techniques
to replace mutated mtDNA with wild-type mtDNA offer women
with high mutation loads the possibility to have a genetically
related child without the risk of transmitting disease.
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